William Blair Has Negative Forecast for Biogen Q2 Earnings

Biogen Inc. (NASDAQ:BIIB) – Analysts at William Blair dropped their Q2 2026 earnings per share (EPS) estimates for shares of Biogen in a research note issued to investors on Thursday, July 31st. William Blair analyst M. Minter now expects that the biotechnology company will post earnings per share of $4.57 for the quarter, down from their prior forecast of $4.60. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen’s Q3 2026 earnings at $3.07 EPS, FY2026 earnings at $15.14 EPS and FY2029 earnings at $18.90 EPS.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.93 by $1.54. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The firm had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.32 billion. During the same quarter in the previous year, the business posted $5.28 earnings per share. The business’s quarterly revenue was up 7.3% compared to the same quarter last year.

Other analysts have also recently issued reports about the company. Hsbc Global Res cut Biogen from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 28th. Wall Street Zen raised Biogen from a “hold” rating to a “buy” rating in a research report on Saturday. Piper Sandler reissued a “neutral” rating and set a $115.00 price objective on shares of Biogen in a research report on Thursday, June 12th. Royal Bank Of Canada upped their target price on shares of Biogen from $208.00 to $219.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Biogen in a research note on Thursday, June 12th. Twenty-one analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $185.63.

Biogen Stock Performance

Shares of BIIB stock opened at $131.95 on Monday. The firm has a 50 day moving average of $129.84 and a two-hundred day moving average of $131.69. The stock has a market capitalization of $19.35 billion, a PE ratio of 12.61, a P/E/G ratio of 1.78 and a beta of 0.13. The company has a quick ratio of 1.79, a current ratio of 2.50 and a debt-to-equity ratio of 0.36. Biogen has a 52 week low of $110.04 and a 52 week high of $213.50.

Institutional Investors Weigh In On Biogen

Several hedge funds have recently modified their holdings of BIIB. Opal Wealth Advisors LLC purchased a new position in Biogen during the 1st quarter worth $26,000. Vision Financial Markets LLC acquired a new stake in Biogen in the first quarter valued at about $27,000. Greykasell Wealth Strategies Inc. purchased a new stake in Biogen in the 1st quarter valued at approximately $27,000. Colonial Trust Co SC increased its position in Biogen by 9,300.0% during the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 186 shares during the period. Finally, Zions Bancorporation National Association UT purchased a new position in shares of Biogen during the 1st quarter worth approximately $29,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Biogen news, insider Rachid Izzar sold 2,223 shares of Biogen stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $135.00, for a total value of $300,105.00. Following the transaction, the insider directly owned 6,330 shares in the company, valued at approximately $854,550. This trade represents a 25.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.